# EDGAR Filing Document

**Accession Number:** 0000748592
**File Stem:** 0001493152-26-030306
**Filing Date:** 2026-6
**Character Count:** 5922
**Document Hash:** 4cb1afdc44201db37b7a8a69c0b297df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-030306.hdr.sgml**: 20260626

**ACCESSION NUMBER**: 0001493152-26-030306

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260622

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260626

**DATE AS OF CHANGE**: 20260626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ernexa Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0000748592
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 311103425
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11460
- **FILM NUMBER:** 261129835

**BUSINESS ADDRESS:**
- **STREET 1:** 1035 CAMBRIDGE STREET
- **STREET 2:** SUITE 18A
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** (617) 798-6700

**MAIL ADDRESS:**
- **STREET 1:** 10531 4S COMMONS DRIVE
- **STREET 2:** SUITE 166-550
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eterna Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20221017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brooklyn ImmunoTherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NTN BUZZTIME INC
- **DATE OF NAME CHANGE:** 20051230

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 22, 2026

**<u>Ernexa Therapeutics Inc.</u>**

*(Exact Name of Registrant as Specified in its Charter)*

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-11460** | **31-1103425** |
| *(State or Other Jurisdiction* | *(Commission* | *(IRS Employer* |
| *of Incorporation)* | *File Number)* | *Identification No.)* |

---

---

| | |
|:---|:---|
| **1035 Cambridge Street, Suite 18A** |  |
| **Cambridge, MA** | **02141** |
| *(Address of Principal Executive Offices)* | *(Zip Code)* |

---

Registrant's telephone number, including area code: **(617) 798-6700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| Common Stock, par value $0.005 per share | ERNA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On June 22, 2026, Sandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., a Delaware corporation (the "<u>Company</u>"), delivered her notice of resignation, with such resignation becoming effective July 3, 2026. Ms. Gurrola's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Following the effective date of her resignation, Ms. Gurrola has agreed to provide transition assistance to the Company on a part-time basis for up to 10 hours per week through the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. The Company has not yet determined the compensation, if any, payable to Ms. Gurrola for such transition services. If the Company enters into or approves a material compensatory arrangement with Ms. Gurrola in connection with her resignation or transition services, the Company will disclose such arrangement in accordance with applicable SEC rules.

The Company has initiated a search to identify a successor. Until a successor is appointed, the Company expects to use additional outside support to assist with finance, accounting, and reporting matters.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

***(d) Exhibits.***

 ****

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Ernexa Therapeutics Inc. | Ernexa Therapeutics Inc. |
| Dated: June 26, 2026 | By: | */s/ Sanjeev Luther* |
|  |  | Sanjeev Luther |
|  |  | President and Chief Executive Officer |

---